Galectin Therapeutics (GALT) Shares Issued (2010 - 2026)

Galectin Therapeutics' Shares Issued history runs 17 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• On a quarterly basis, Shares Issued fell 9.9% year-over-year to $7.2 million in Q1 2026; TTM through Mar 2026 was $7.2 million, a 9.9% decrease from a year earlier, with the FY2025 full-year figure at $6.6 million, down 4.12% from the prior year.
• Shares Issued improved to $7.2 million in Q1 2026 per GALT's latest filing, from $6.6 million in the prior quarter.
• Across five years, Shares Issued topped out at $8.0 million in Q1 2025 and bottomed at $5.6 million in Q1 2022.
• The 5-year median for Shares Issued is $6.6 million (2025), against an average of $6.7 million.
• Across the five-year window, Shares Issued advanced 21.13% in 2022 and slipped 9.9% in 2026, its largest moves.
• Year by year, Shares Issued stood at $5.7 million in 2022, then rose by 10.24% to $6.3 million in 2023, then climbed by 8.22% to $6.9 million in 2024, then declined by 4.12% to $6.6 million in 2025, then gained by 9.66% to $7.2 million in 2026.
• Per Business Quant, the three latest GALT Shares Issued figures stand at $7.2 million (Q1 2026), $6.6 million (Q4 2025), and $7.3 million (Q3 2025).